

FORM PTO-1449
(REV. 7-80)INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO. KIR92-
01A4

SERIAL NO. 08/690,775

APPLICANTS Marc Feldmann and Ravinder N. Maini

FILING DATE

August 1, 1996

GROUP

~~1806~~ 1644

U.S. PATENT DOCUMENTS

EXA M- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
<i>AO</i>	AO	WO 92/16553	01-OCT-92	PCT			
<i>AP</i>	AP	WO 95/09652	13-APR-95	PCT			
<i>AQ</i>	AQ	WO 96/33204	24-OCT-96	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>AX3</i>	AX3	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 7 :191-297 (1995).
<i>AY3</i>	AY3	Bologna, C., and Sany, J., "Association des Traitements de Fond dans la Polyarthrite Rhumatoïde," <i>Presse Med.</i> , 25:876-878 (1996).
<i>AZ3</i>	AZ3	Borigini, M.J., and Paulus, H.E., "Combination Therapy," <i>Baillière's Clin. Rheum.</i> , 9(4):689-710 (1995).
<i>AR4</i>	AR4	Kalden, J.R., and Manger, B., "Biologic Agents in the Treatment of Inflammatory Rheumatic Diseases," <i>Curr. Opin. Rheum.</i> , 9:206-212 (1997).
<i>AS4</i>	AS4	Kavanaugh, A., et al., "Anti-TNF- α Monoclonal Antibody (mAb) Treatment of Rheumatoid Arthritis (RA) Patients With Active Disease On Methotrexate (MTX); Results of a Double-Blind, Placebo Controlled Multicenter Trial," <i>Arth. Rheum.</i> , 39(Suppl.9): 18-22 (October 1996), Abstract 575.

EXAMINER

PHILLIP GAMMEL

DATE CONSIDERED

8/25/98